The Research Executive Committee is closely involved with the program planning and evaluation activities of the UPCI. Discussions regarding the scientific activities and growth ofthe scientific programs are on the agenda on a regular basis. Similarly, the services provided by UPCI shared facilities, operational efficiencies and the need for new services are also discussed regularly. A formal presentation ofthe research activities ofthe CCSG programs, developing programs and services provided bythe shared facilities are presented to the Scientific Advisory Council (SAC) members of UPCI at the annual SAC meeting, following which SAC's feedback and recommendations are discussed at the quarterly Program Leaders and Shared Facility Directors meeting to get their input. The Research Executive Committee continues to discuss extensively the recommendations provided by SAC and the subsequent comments by the Program Leaders and Shared Facility Directors to take the appropriate steps to enhance the programs and shared facilities. The Annual Scientific Retreat provides an outstanding opportunity for lab based faculty, medical and hematologic oncologists, residents, clinical fellows, postdoctoral fellows (lab based) and graduate students to meet together and share ideas. The 2-day event also provides the opportunity to hear presentations from newly recruited faculty members as well as from established UPCI members who have innovative and important research findings. Funds are being requested for two aspects of UPCI's program planning and evaluation activities. These are funds for annual meetings of UPCI's Scientific Advisory Committee, and the UPCI Annual Scientific Retreat.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705427
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$84,479
Indirect Cost
$28,593
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Yang, Liangchun; Xie, Min; Yang, Minghua et al. (2014) PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nat Commun 5:4436
Zhang, Xuan; Bresee, Jamee; Fields, Gregg B et al. (2014) Near-infrared triple-helical peptide with quenched fluorophores for optical imaging of MMP-2 and MMP-9 proteolytic activity in vivo. Bioorg Med Chem Lett 24:3786-90
Oborski, Matthew J; Demirci, Emre; Laymon, Charles M et al. (2014) Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme. Clin Nucl Med 39:e431-2
Gross, Neil D; Bauman, Julie E; Gooding, William E et al. (2014) Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clin Cancer Res 20:3289-98
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Peterson, Lanell M; Kurland, Brenda F; Schubert, Erin K et al. (2014) A phase 2 study of 16*-[18F]-fluoro-17*-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Mol Imaging Biol 16:431-40
Sun, Xiaofang; Tang, Daolin (2014) HMGB1-dependent and -independent autophagy. Autophagy 10:1873-6
Pollock, Sheri L; Rush, Elizabeth A; Redner, Robert L (2014) NPM-RAR, not the RAR-NPM reciprocal t(5;17)(q35;q21) acute promyelocytic leukemia fusion protein, inhibits myeloid differentiation. Leuk Lymphoma 55:1383-7
Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18
Popovtzer, Aron; Normolle, Daniel; Worden, Francis P et al. (2014) Phase I trial of radiotherapy concurrent with twice-weekly gemcitabine for head and neck cancer: translation from preclinical investigations aiming to improve the therapeutic ratio. Transl Oncol 7:479-83

Showing the most recent 10 out of 463 publications